$0.45 Earnings Per Share Expected for BioTelemetry Inc (NASDAQ:BEAT) This Quarter

Equities research analysts predict that BioTelemetry Inc (NASDAQ:BEAT) will report $0.45 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for BioTelemetry’s earnings, with the lowest EPS estimate coming in at $0.44 and the highest estimate coming in at $0.46. BioTelemetry posted earnings per share of $0.46 during the same quarter last year, which indicates a negative year over year growth rate of 2.2%. The business is expected to issue its next earnings results on Wednesday, July 24th.

On average, analysts expect that BioTelemetry will report full year earnings of $1.90 per share for the current financial year, with EPS estimates ranging from $1.81 to $2.01. For the next financial year, analysts anticipate that the company will post earnings of $2.08 per share, with EPS estimates ranging from $1.95 to $2.20. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover BioTelemetry.

BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.42. BioTelemetry had a net margin of 11.86% and a return on equity of 23.36%. The company had revenue of $103.98 million for the quarter, compared to analysts’ expectations of $104.17 million. During the same quarter in the previous year, the company earned $0.39 earnings per share. BioTelemetry’s quarterly revenue was up 10.0% on a year-over-year basis.

BEAT has been the topic of several research analyst reports. BidaskClub cut shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 23rd. ValuEngine cut shares of BioTelemetry from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Dougherty & Co restated a “buy” rating and issued a $75.00 price objective (down previously from $81.00) on shares of BioTelemetry in a report on Friday, April 26th. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $84.00 price objective on the stock in a report on Thursday, February 28th. Finally, Benchmark set a $82.00 price objective on shares of BioTelemetry and gave the stock a “buy” rating in a report on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. BioTelemetry has an average rating of “Buy” and an average price target of $79.57.

Shares of NASDAQ BEAT traded down $1.62 during midday trading on Wednesday, hitting $46.88. 17,081 shares of the company traded hands, compared to its average volume of 364,088. BioTelemetry has a 12-month low of $43.30 and a 12-month high of $80.92. The company has a current ratio of 1.99, a quick ratio of 1.84 and a debt-to-equity ratio of 0.57. The firm has a 50-day moving average of $49.22. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 24.13 and a beta of 1.42.

In other BioTelemetry news, Director Kirk E. Gorman sold 5,518 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $53.69, for a total value of $296,261.42. Following the sale, the director now owns 178,833 shares in the company, valued at $9,601,543.77. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.50% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its stake in shares of BioTelemetry by 2.7% in the fourth quarter. BlackRock Inc. now owns 5,092,773 shares of the medical research company’s stock worth $304,141,000 after buying an additional 134,956 shares in the last quarter. Eagle Asset Management Inc. bought a new position in shares of BioTelemetry in the first quarter worth approximately $31,052,000. Carillon Tower Advisers Inc. lifted its stake in shares of BioTelemetry by 284.2% in the first quarter. Carillon Tower Advisers Inc. now owns 478,632 shares of the medical research company’s stock worth $29,972,000 after buying an additional 354,043 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of BioTelemetry by 11.8% in the fourth quarter. Geode Capital Management LLC now owns 376,618 shares of the medical research company’s stock worth $22,490,000 after buying an additional 39,722 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of BioTelemetry by 119.7% in the fourth quarter. Deutsche Bank AG now owns 310,751 shares of the medical research company’s stock worth $18,556,000 after buying an additional 169,306 shares in the last quarter. Institutional investors and hedge funds own 90.66% of the company’s stock.

BioTelemetry Company Profile

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.

Recommended Story: What are no-load funds?

Get a free copy of the Zacks research report on BioTelemetry (BEAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.